Clinical Research Directory
Browse clinical research sites, groups, and studies.
Empagliflozin Reversal of Arterial StiffnEss in Aging
Sponsor: University of Missouri-Columbia
Summary
Randomized placebo-controlled clinical trial in a cohort of males (n=40) and females (n=40), 60-80 years of age, with the hypothesis that SGLT2 inhibition with empagliflozin (10mg/day for 12 weeks) reduces aging-related arterial stiffening.
Official title: SGLT2 Inhibition as a Therapeutic Strategy to Reverse Arterial Stiffening in Aging
Key Details
Gender
All
Age Range
60 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2024-08-18
Completion Date
2029-02-28
Last Updated
2026-02-06
Healthy Volunteers
Yes
Conditions
Interventions
Empagliflozin 10 MG
10mg Empagliflozin daily for 12 weeks
Placebo
10mg Placebo daily for 12 weeks
Locations (1)
University of Missouri
Columbia, Missouri, United States